@lilbex01's three-week Ozempic results, fact-checked

What did @lilbex01 actually say?

She weighed in at 84 kg after starting at 87.7 kg at her doctor's visit before beginning semaglutide, which works out to 3.7 kg lost over roughly three weeks. She says her appetite is "dramatically reduced" and that she has to force herself to eat breakfast, adding that skipping meals entirely would be easy. She also noted mild nausea from the injection, described it as "nothing I can't handle," and mentioned an upcoming blood test to monitor whether the medication is working alongside her other tablets.

One thing she was clear about: she was prescribed semaglutide by a doctor for a reason she covered in earlier episodes, not purely for weight loss. That context matters, and she deserves credit for saying it repeatedly.

She also mispronounced Ozempic as "Mozambique" throughout, which is harmless but worth flagging since this is a medication name, not a country.

Does the science back this up?

The weight loss rate is fast, but not implausible for early semaglutide use. The appetite suppression claims are well-supported by clinical evidence. The nausea she describes is one of the most documented side effects in the literature.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) followed 1,961 adults on 2.4 mg semaglutide weekly and found average weight loss of around 14.9% of body weight over 68 weeks. Early weeks tend to show faster losses, partly from fluid and glycogen shifts, so 3.7 kg in three weeks is within the range of what gets reported, though it is on the higher end. Semaglutide works primarily by slowing gastric emptying and acting on GLP-1 receptors in the brain to reduce appetite, which lines up exactly with her description of reduced hunger. Nausea affects roughly 44% of patients on semaglutide in clinical trials (Davies et al., 2021, Lancet), most commonly in the early weeks at lower doses.

What did they get wrong (or right)?

The appetite suppression and nausea descriptions are accurate and consistent with the pharmacology. The weight loss figure is plausible. But one thing she said deserves a closer look: "I have to force myself to eat breakfast every morning. Otherwise I could go all day not eating. And that is not healthy."

She is right that going all day without eating is not ideal on semaglutide, but the framing underplays how serious this can be. Chronic undereating on GLP-1 medications can lead to muscle loss rather than fat loss, micronutrient deficiencies, and in people with diabetes, dangerous blood sugar fluctuations. Research from Bikou et al. (2023, Nutrients) found that patients on GLP-1 agonists who do not maintain adequate protein intake lose significantly more lean mass than fat mass. Forcing breakfast is the right instinct, but viewers watching this who also feel like skipping meals should know there are real clinical risks to that pattern, not just a vague sense that it is unhealthy.

She also said the blood test will show "if the needle along with the medication is working." Semaglutide is the medication. This phrasing suggests she may be taking both an injectable and an oral medication, which is clinically plausible, but conflating efficacy monitoring for two different drugs in one sentence could confuse viewers about what is being measured.

What should you actually know?

Early weight loss on semaglutide is real, but a significant portion of it in the first few weeks is not fat. It includes water weight and glycogen depletion. That does not make it meaningless, but it does mean the scale dropping fast early does not always translate to the same rate continuing. The STEP trials showed the most dramatic losses tended to slow and plateau, which is normal physiology, not a sign the drug has stopped working.

The reduced appetite effect she describes is one of semaglutide's core mechanisms. But reduced appetite does not mean reduced nutritional need. Protein targets, micronutrient intake, and regular meals still matter. Anyone on a GLP-1 medication who finds themselves skipping meals or eating very little should raise that with their prescriber, not just push through it as a side benefit of the drug.

Finally, blood monitoring is genuinely important and her mention of an upcoming test is a good sign. HbA1c, liver enzymes, kidney function, and lipid panels can all shift on semaglutide, and regular monitoring is part of responsible use. The fact that she has a prescribing doctor and is doing blood tests puts her in a better position than many people self-sourcing GLP-1 medications online.